Autonomy University

Autonomy Bio is a San Francisco-based biotechnology company founded in 2024 that focuses on drug discovery for longevity and healthspan extension. The company utilizes a platform approach to develop combinatorial small molecule therapies targeting the biological hallmarks of aging, with a specific emphasis on cardiometabolic health. Autonomy Bio is notable for its proactive engagement with the FDA to establish novel clinical endpoints for aging, aiming to move beyond traditional mortality data toward functional and resilience-based outcomes. In early 2025, the company secured $17 million in startup funding to advance its pipeline of age-related therapeutics.